NASDAQ:TXMD - TherapeuticsMD Stock Price, Price Target & More

TherapeuticsMD trades on the NASDAQ under the ticker symbol "TXMD."

TherapeuticsMD Inc (NASDAQ:TXMD) released its quarterly earnings results on Tuesday, February, 20th. The company reported ($0.10) earnings per share for the quarter, missing analysts' consensus estimates of ($0.09) by $0.01. The firm had revenue of $4.13 million for the quarter, compared to the consensus estimate of $4.66 million. TherapeuticsMD had a negative net margin of 458.49% and a negative return on equity of 63.67%. The firm's revenue for the quarter was down 8.0% on a year-over-year basis. During the same period in the previous year, the business earned ($0.12) earnings per share. View TherapeuticsMD's Earnings History.

9 brokers have issued 12 month price targets for TherapeuticsMD's shares. Their forecasts range from $6.00 to $28.00. On average, they anticipate TherapeuticsMD's stock price to reach $14.50 in the next twelve months. View Analyst Ratings for TherapeuticsMD.

TherapeuticsMD saw a increase in short interest in March. As of March 29th, there was short interest totalling 57,501,783 shares, an increase of 0.8% from the March 15th total of 57,941,715 shares. Based on an average trading volume of 1,926,644 shares, the short-interest ratio is presently 29.8 days. Currently, 33.1% of the company's shares are sold short.

Some companies that are related to TherapeuticsMD include Acadia Pharmaceuticals (ACAD), Supernus Pharmaceuticals (SUPN), Puma Biotechnology (PBYI), Akorn (AKRX), Global Blood Therapeutics (GBT), Horizon Pharma (HZNP), The Medicines (MDCO), AnaptysBio (ANAB), Portola Pharmaceuticals (PTLA), Heron Therapeutics (HRTX), Motif (MTFB), Intercept Pharmaceuticals (ICPT), Corcept Therapeutics (CORT), Spectrum Pharmaceuticals (SPPI), Esperion Therapeutics (ESPR), Arena Pharmaceuticals (ARNA), Aimmune Therapeutics (AIMT) and Insmed (INSM).

News articles about TXMD stock have trended somewhat positive on Friday, according to Accern. The research group rates the sentiment of press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. TherapeuticsMD earned a news impact score of 0.22 on Accern's scale. They also gave press coverage about the company an impact score of 45.03 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near term.

Shares of TXMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of TXMD stock can currently be purchased for approximately $5.85.

TherapeuticsMD has a market capitalization of $1.26 billion and generates $16.78 million in revenue each year. The company earns $-76,920,000.00 in net income (profit) each year or ($0.37) on an earnings per share basis. TherapeuticsMD employs 173 workers across the globe.

TherapeuticsMD's mailing address is 6800 BROKEN SOUND PARKWAY NW, BOCA RATON FL, 33487. The company can be reached via phone at 561-961-1900 or via email at [email protected]